This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Holman, M.A. & Munzer, S.R. 85 Iowa L. Rev. 735, 753–754 (2000).
Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156, 164–165 (4th Cir. 1958). See also Diamond v. Chakrabarty, 447 US 303, 309 (1980)(“Congress intended statutory subject matter to 'include anything under the sun that is made by man.'”).
See, e.g., Harnett, C.J. Risk—Issues In Health & Safety (Spring 1994); Dastgheib-Vinarov, S. Marq. Intell. Prop. L. Rev. 4, 143 (2000); Eisenberg, R.S. Emory L.J. 49, 783 (2000); Auth, D.R. Nat. Biotechnol. 15, 911–912 (1997).
66 Fed. Reg. 1092 (2001), available at http://www.uspto.gov/web/menu/current.html#register. See also Revised Interim Utility Guidelines Training Materials available at http://www.uspto.gov/web/patents/guides.htm; Kowalski, T.J. Nat. Biotechnol. 18, 349–350 (2000).
927 F.2d 1200, 1206 (Fed. Cir. 1991).
984 F.2d 1164, 1170 (Fed. Cir. 1993).
See Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 US 17 (1997).
Markman v. Westview Instruments, Inc., 517 US 370 (1996).
Id.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Flattmann, G., Kaplan, J. Patenting expressed sequence tags and single nucleotide polymorphisms. Nat Biotechnol 19, 683–684 (2001). https://doi.org/10.1038/90309
Issue Date:
DOI: https://doi.org/10.1038/90309
This article is cited by
-
Patenting expressed sequence tags and single nucleotide polymorphisms
Nature Biotechnology (2001)